Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Data Demonstrate that KP415 Can Be Administered without Regard to Food; Can Be Mixed into Foods or Drink CELEBRATION, Fla., Oct. 22, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq: KMPH), a...
-
CELEBRATION, Fla., Sept. 20, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced...
-
CELEBRATION, Fla., Sept. 17, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced...
-
CELEBRATION, Fla., Sept. 05, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today...
-
Up to a Total of $493 Million in Upfront, Sales and Development Milestone Payments, as well as Royalties on Net Sales KemPharm Will Host a Conference Call and Live Audio Webcast with Slide...
-
CELEBRATION, Fla., Aug. 13, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today...
-
Development & Regulatory Highlights: Completed KP415 Pre-NDA Meeting with FDAProvided Update on APADAZ® Formulary AdoptionAnnounced FDA Approval of sNDA for Two Additional Strengths of APADAZ ...
-
KP415 NDA Filing Anticipated in Late Q2 or Early Q3 2019 Conference Call Scheduled for Today, Thursday, April 11, 2019 at 5:00 p.m. ET CELEBRATION, Fla., April 11, 2019 (GLOBE NEWSWIRE) --...
-
Conference Call Scheduled for Today, Wednesday, March 13, 2019 at 8:30 a.m. ET Highlights: According to MMIT estimates, the authorized generic for APADAZ has unrestricted formulary access for 91% of...
-
CELEBRATION, Fla., March 05, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today...